Cargando…

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance

Chimeric antigen receptor (CAR)-T cells already showed impressive clinical regressions in leukemia and lymphoma. However, the development of CAR-T cells against solid tumors lags behind. Here we present the clinical-scale production of CAR-T cells for the treatment of melanoma under full GMP complia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiesinger, Manuel, März, Johannes, Kummer, Mirko, Schuler, Gerold, Dörrie, Jan, Schuler-Thurner, Beatrice, Schaft, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Technical Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721485/ https://www.ncbi.nlm.nih.gov/pubmed/31426437 http://dx.doi.org/10.3390/cancers11081198

Ejemplares similares

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
por: Simon, Bianca, et al.
Publicado: (2018)

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019)

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
por: Dörrie, Jan, et al.
Publicado: (2020)

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
por: Koch, Elias A. T., et al.
Publicado: (2022)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

CARs: Beyond T Cells and T Cell-Derived Signaling Domains
por: Sievers, Nico M., et al.
Publicado: (2020)

The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023)

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
por: Teppert, Karin, et al.
Publicado: (2023)

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
por: Gerer, Kerstin F., et al.
Publicado: (2017)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

Just One Position-Independent Lysine Residue Can Direct MelanA into Proteasomal Degradation following N-Terminal Fusion of Ubiquitin
por: Setz, Christian, et al.
Publicado: (2013)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Human Adenovirus-Specific γ/δ and CD8(+) T Cells Generated by T-Cell Receptor Transfection to Treat Adenovirus Infection after Allogeneic Stem Cell Transplantation
por: Dörrie, Jan, et al.
Publicado: (2014)

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
por: Dörrie, Jan, et al.
Publicado: (2018)

The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
por: Schaft, Niels
Publicado: (2020)

NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells
por: Bosch, Naomi C., et al.
Publicado: (2019)

A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells †
por: Bosch, Naomi C., et al.
Publicado: (2021)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells
por: Hoyer, Stefanie, et al.
Publicado: (2015)

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA
por: Moreira, Alvaro, et al.
Publicado: (2020)

IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities
por: Du, Li, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Arthroscopic Treatment of Hip Chondral Defects With Bone Marrow Stimulation and BST-CarGel
por: Tey, Marc, et al.
Publicado: (2015)

Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent
por: Bodbin, Sara E., et al.
Publicado: (2020)

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023)

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
por: Boscheinen, Jan B., et al.
Publicado: (2019)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Development of a Car-mounted Mobile MR Imaging System for Diagnosis of Sports-related Wrist Injury
por: Miyasaka, Tomoki, et al.
Publicado: (2022)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Reduced Cytotoxicity by Repetitive mRNA Transfection in Differentiated Neurons
por: Ko, Seung Hwan, et al.
Publicado: (2022)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Motor Cars for Doctors: Cars Suitable for Practitioners
Publicado: (1906)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
por: Fernández, Lucía, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bprc4fbib22nhmjrr6al39oc82